- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Eye on Pharma: Xbrane to Shift Its Focus to Biosimilars
Xbrane’s lead biosimilar candidate is a ranibizumab product (referencing Lucentis), developed in collaboration with Stata, that is moving into a pivotal clinical trial. The study will enroll patients with wet age-related macular degeneration across 16 countries.
Xbrane Biopharma has announced that it will shift its focus from generic drugs to biosimilars. “The board of directors of Xbrane has decided to dedicate the absolute majority of the company's development resources to biosimilars going forward,” the drug maker announced in a statement on September 10.
As part of Xbrane’s shift to biosimilars, the company will only pursue further development of its generic long-acting risperidone, leuprolide, exenatide, and octreotide products if additional resources become available internally or via strategic partnerships. It will, however, continue to develop its long-acting triptorelin injectable, a treatment for advanced prostate cancer. The freed-up resources from generic development will allow the company to pursue its pipeline of biosimilars.
Click to read more about Xbrane.
Xbrane’s lead biosimilar candidate is a ranibizumab product (referencing Lucentis), developed in collaboration with Stata, that is moving into a pivotal clinical trial. The study will enroll patients with wet age-related macular degeneration across 16 countries. In July 2018, Xbrane and Stada announced their development agreement for the product, under which each organization will contribute equally to development expenses and share profits from commercialization of the proposed biosimilar. Additionally, Stada agreed to make an upfront payment to Xbrane of approximately $8.7 million to fund development.
Also under development by Xbrane are a certolizumab pegol product (referencing Cimzia) and a pegaspargase product (referencing Oncaspar) for the treatment of acute lymphocytic leukemia.
The company says that it is also beginning development of 2 products that have patents expiring between 2026 and 2028. Said chairman Anders Tullgren, “We see multiple attractive opportunities to address and we have decided to develop [2] biosimilars on [2] fast growing biologics with a current combined global sale well above [$5 billion] with patent expiration 2026-2028. Now is the right time to initiate development of biosimilars to these biologics and we see the opportunity to be ahead of the game and to be amongst the first to launch."
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
